232615-10-0

Basic information

• Product Name: TERT-BUTYL 1,2,2-TRIMETHYLHYDRAZINE-1-CARBOXYLATE
• Synonyms: N,N,N'-TRIMETHYLHYDRAZINE, N'-BOC PROTECTED;TERT-BUTYL 1,2,2-TRIMETHYLHYDRAZINE-1-CARBOXYLATE;tert-butyl 1,2,2-triMethylhydrazinecarboxylate;tert-butyl trimethylhydrazinecarboxylate
• CAS NO: 232615-10-0
• Molecular Formula: C₈H₁₈N₂O₂
• Molecular Weight: 174.242
• Mol File: 232615-10-0.mol

Chemical Properties

• Boiling Point: 191.136°C at 760 mmHg
• Flash Point: 69.397°C
• Appearance: /
• Density: 0.975g/cm³
• Vapor Pressure: 0.523mmHg at 25°C
• Refractive Index: 1.453
• CAS DataBase Reference: TERT-BUTYL 1,2,2-TRIMETHYLHYDRAZINE-1-CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: TERT-BUTYL 1,2,2-TRIMETHYLHYDRAZINE-1-CARBOXYLATE(232615-10-0)
• EPA Substance Registry System: TERT-BUTYL 1,2,2-TRIMETHYLHYDRAZINE-1-CARBOXYLATE(232615-10-0)

Safety Data

• Hazardous Substances Data: 232615-10-0(Hazardous Substances Data)

Usage

InChI:InChI=1/C8H18N2O2/c1-8(2,3)12-7(11)10(6)9(4)5/h1-6H3

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 74-88-4 methyl iodide 
• 50-00-0 formaldehyd 
• 21075-83-2 1-methyl-1-tert-butoxycarbonylhydrazine 
• 870-46-2 t-butoxycarbonylhydrazine 

Downstream Products

• 1741-01-1 Trimethylhydrazin 

Relevant articles and documents

Synthesis and Properties of Higher Nuclearity Polyazanes

Polyazanes (i.e., higher nuclearity homologues of hydrazines) with increasing numbers of bound nitrogen atoms (from 3 to 5), including the first pentazane ever described, were prepared by the addition of lower-order polyazanes to diazo reagents. A structure was obtained. It was shown that the polynitrogen chains adopt a helical conformation. DFT modeling shows that the arrangement persists in solution. Although the polyazanes are all reducing agents, they become less so as the number of nitrogens increases.

Preparation method of anamorelin intermediate

The invention relates to the field of medicine synthesis, in particular to a preparation method of an anamorelin intermediate. On one hand, 1-boc-1-methylhydrazine is taken as a reaction material, anda key intermediate tert-butyl N,N',N'-trimethylhydrazinecarboxylate is prepared in one pot with a formaldehyde compound and palladium catalyst/hydrogen source alternative reaction method. The methodis simple to operate, and the used raw material is safe and easy to obtain; compared with the prior art, the method has the increased yield; on the other hand, in the method, tert-butyl N,N',N'-trimethylhydrazinecarboxylate and hydrochloric acid are subjected to a reaction in an organic solvent, and a high-yield and high-purity crystallized product of N,N',N'-trimethylhydrazine hydrochloride can be directly obtained, and the crystallized product is not required to be further purified and is low in moisture absorption, convenient to store and very suitable for industrial mass production.

Use of polyanions for alkylation of hydrazine derivatives

Alkylation of hydrazine and its derivatives still remains a quite complicated task. The novel method utilizing the polyanion strategy is reported. Formation and use of trianion for alkylation of hydrazine derivatives is first reported. Described method pr

COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES

Compounds of the general formula I and their use for treating medical disorders resulting from a deficiency in growth hormone.

Growth hormone secretagogues derived from NN703 with hydrazides as C- terminal

A series of GH secretagogues based on modifications in the C-terminal of NN703 is reported. The C-terminal N-methyl amide of NN703 has been replaced with alkylated hydrazides in order to decrease the volume of distribution and identify GH secretagogues with shorter duration of action. Most of the prepared compounds show high potency in a rat pituitary assay. Subsequent to an initial in vivo screening in dogs, four compounds were selected for further pharmacological and pharmacokinetic evaluation. The four compounds showed oral bioavailability around 35% and equipotency in vitro compared to NN703. The relationship between lipophilicity and volume of distribution is discussed and it is speculated whether the lower volume of distribution is attributed to the observed higher in vivo potency and shorter plasma elimination half-life. (C) 2000 Editions scientifiques et medicales Elsevier SAS.

Compounds with growth hormone releasing properties

Compounds of Formula I and their use for treating medical disorders resulting from a deficiency in growth hormone are disclosed, wherein R1, R2, R3a, R4a, R5a, G, J and D are as defined in the specification.